Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults.

For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

Roche’s Genentech unit is to partner with South Korea’s Hanmi Pharmaceutical, to develop and market a phase 1 cancer drug, in a deal potentially worth over $900 million. Under the agreement ...

The US Food and Drug Administration (FDA) has granted priority review to Genentech's advanced bladder cancer drug, atezolizumab. The Roche unit said yesterday that the FDA is set to make a ...

AstraZeneca's Imfinzi was used before and after surgery in a clinical trial of patients with muscle-invasive bladder cancer — ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.

Genentech, a leading biotechnology company ... The company also worked to develop checkpoint inhibitors, which is a class of immunotherapy drugs that redirect immune cells to target cancer. As ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults. The treatment, called Tecentriq Hybreza ...